Yucel H, Yucel A, Arbag H, Cure E, Eryilmaz MA, Ozer AB
Segments Covered in This Report By Mechanism of Action GLP-1 Receptor Agonists Dual GIP/GLP-1 Agonists Triple or Multi-Receptor Agonists Centrally Acting Sympathomimetics Peripherally Acting Lipase Inhibitors By Drug Type Prescription Drugs OTC Drugs By Route of Administration Injectable (Weekly / Monthly) Oral Daily Pills By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies & Tele-health Platforms Weight-Loss Clinics Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan India South Korea Australia Rest of Asia-Pacific Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America Data Sources, Market Sizing, and Validation Primary Research Endocrinologists, payers, pharmacists, and supply-chain executives across North America, Europe, Asia-Pacific, and the Gulf were interviewed to confirm real-world adherence, mark-ups, and production ramp-ups
Appetite Regulation: GLP-1 targets specific areas of the brain that control hunger and the sensation of fullness
Further Reading Wellness Wants in on the Ozempic Economy From supplements to workout plans, the term GLP-1, the hormone associated with Ozempic, is popping up on a widespread range of new products as wellness brands join in on the weight loss drug boom
Participants lost an average of ~12 lbs
Youll start by speaking with a registered nurse, no upfront payment required
